Opinion
Video
Author(s):
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is defined by its sensitivity to androgen deprivation therapy, while metastatic hormone-sensitive prostate cancer (mHSPC) emphasizes the cancer’s responsiveness to hormone treatment, highlighting the nuanced differences in patient management strategies.
Video content above is prompted by the following:
How do you define mCSPC and mHSPC? How are they different? (Lowrance et al. AUA/SUO Guideline, 2023) (NCCN, Prostate Cancer, v4.2024)